SCHEMBL508325

SCHEMBL508325

CC(C)(C)OC(=O)NCC1(C=O)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
EPHX1 P07099 1/20 0.38
CTSK P43235 3/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
DRD2 P14416 3/20 0.36
APLNR P35414 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28055196 0.93 HCRTR2 (0.40) HCRTR2TDP1MAOAMAOBMEN1
SCHEMBL5962444 0.92 EPHX1 (0.41) HCRTR2TDP1MAOAMAOBMEN1
SCHEMBL18182483 0.89 HCRTR2 (0.43) HCRTR2TDP1MAOAMAOBMEN1
SCHEMBL23219989 0.83 HCRTR2 (0.37) HCRTR2TDP1MAOAMAOBMEN1
SCHEMBL21606412 0.83 HCRTR2 (0.37) HCRTR2TDP1MAOAMAOBMEN1
SCHEMBL24463788 0.83 HCRTR2 (0.37) HCRTR2TDP1MAOAMAOBMEN1
SCHEMBL31446944 0.82 HCRTR2 (0.39) HCRTR2TDP1MAOAMAOBMEN1
SCHEMBL6183787 0.79 NAMPT (0.43) DRD2
SCHEMBL28055283 0.79 HCRTR2 (0.39) HCRTR2TDP1MAOAMAOBMEN1
SCHEMBL30419638 0.78 HCRTR2 (0.41) HCRTR2TDP1MAOAMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353817-A1 INTERLUKIN-17A INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-11-20 US disclosed
US-20250154138-A1 Small Molecule IL-17A Modulators BEIGENE, LTD. (KY) 2025-05-15 US disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
CN-119233974-A Indolone derivative and application thereof 康百达(四川)生物医药科技有限公司 2024-12-31 CN disclosed
CN-119053589-A Small molecule IL-17A modulators 百济神州有限公司 2024-11-29 CN disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
WO-2024017372-A1 INDOLONE DERIVATIVE AND USE THEREOF 成都百裕制药股份有限公司 2024-01-25 WO disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 EP disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2010132759-A1 ANTIBACTERIAL DERIVATIVES OF DIBEKACIN ACHAOGEN, INC. (US) 2010-11-18 WO disclosed
EP-2217610-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Achaogen, Inc. (US) 2010-08-18 EP disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
WO-2010042851-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-15 WO disclosed
WO-2010042851-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-15 WO disclosed
WO-2010042850-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-15 WO disclosed
WO-2010042850-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-15 WO disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353817-A1 INTERLUKIN-17A INHIBITORS AND USES THEREOF IL17A, IL15, IL23R HCRTR2 4221/4885TDP1 3198/4885MAOA 1626/4885
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, MRPL9, NQO2 HCRTR2 4824/4885TDP1 2209/4885MAOA 3073/4885
US-20250154138-A1 Small Molecule IL-17A Modulators IL17A, IL23R, IL2 HCRTR2 4184/4885TDP1 4098/4885MAOA 4092/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 HCRTR2 600/4885TDP1 2792/4885MAOA 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.